IONS ionispharma.com Company Profit

Corporate emblem and logo of Ionis (IONS)

Ionis Pharmaceuticals specializes in advanced RNA technologies to combat severe brain pathologies. The company's net profit margin on this chart reflects a trend where the indicator value is -0.57. Cash flow remains volatile due to high R&D expenditures and one-time partner payments. The business is currently scaling its therapy portfolio by launching approved drugs into the global market.

IONS Ionis Pharmaceuticals Company Net Income (07/04/2022 - 10/30/2026)

Analytical breakdowns and data insights for company Ionis (IONS)

- stock value and consensus price forecast:
Market Price Isis Pharmaceuticals|IONS - Price Target Chart
- market capitalization data:
Market Capitalization Isis Pharmaceuticals|IONS - Enterprise Value
- book capitalization information:
Net Assets per Share Ionis|IONS - Company Book Value|Market Capitalization to Book Value ionispharma.com|IONS - Cumulative Company Assets
- debt burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio Ionis Pharmaceuticals|IONS - Long-Term Debt to Equity|Current Liabilities to Equity Ionis Pharmaceuticals, Inc.|IONS - Company Aggregate Debts|Debt to Net Assets Ratio Isis Pharmaceuticals|IONS - Company Long-Term Debts|Company Short-Term Debts Ionis|Intermediate Coverage Ratio ionispharma.com
- earnings and multiples data:
IONS - Company Net Income
Fundamental valuation:Isis Pharmaceuticals (IONS)
Manufactured products of ionispharma.com

The indicator is calculated as the difference between total revenues and all operating expenses in real time. This metric measures capital management efficiency and the sustainability of business margins. For Ionis Pharmaceuticals (IONS), this confirms the monetization of lifelong therapies for rare pathologies. A stable cash flow from unique drugs minimizes liquidity risks. Analyzing the company's current profit allows for a real-time assessment of the pace at which these advantages are being capitalized.

Direct competitors

Company Net Income Tempus AI (TEM)|Company Net Income Qiagen N.V.|Company Profit RGEN (repligen.com)|Net Profit RNA|Net Financial Result CRISPR Therapeutics Inc|Company Net Income Sema4 WGS|Net Financial Result Ultragenyx Corp (RARE)|BEAM: Net Income|Final Profit SRPT (sarepta.com)|Twist Bioscience, Inc. (TWST) - Company Net Income|Profit After Tax TXG (10x Genomics Inc)|NTLA (Intellia) - Net Profit|STOK: Final Profit|Net Profit BLFS|Net Profit wavelifesciences.com (WVE)|Company Net Income Maze Therapeutics MAZE|Final Profit SION|PRME - Company Net Income|Taysha Corp (TSHA) - Net Income|QURE: Net Profit|meiragtx.com (MGTX) - Net Profit|RGNX (REGENXBIO) - Net Profit|Net Income Solid Biosciences Inc (SLDB)|Net Profit OCGN|PACB - Company Net Income|Benitec Biopharma Inc. - Net Income|Net Profit designtx.com DSGN|RCKT: Net Income|4DMT - Profit After Payment of Taxes|LXEO: Net Profit|KRRO - Net Financial Result|EDIT (Editas Medicine, Inc.) - Net Profit|Net Income silence-therapeutics.com (SLN)|Net Profit PRQR|Net Profit codexis.com (CDXS)|Company Net Income Sangamo SGMO|Nautilus Biotechnology, Inc. - Company Net Income|MGX - Company Net Income|Net Financial Result Precision BioSciences Inc. DTIL|GBIO: Net Profit|BOLD - Net Financial Result|Company Net Income Exicure Inc.|Company Net Income Celsion Corporation IMNN|Company Net Income Phio Pharmaceuticals (PHIO)|mustangbio.com - Company Profit|Company Net Income TransCode Therapeutics, Inc. RNAZ|Net Financial Result Bionano Genomics Inc. (BNGO)|Applied DNA - Net Profit|BLUE (bluebird bio, Inc) - Company Profit|immunoprecise.com (IPA) - Company Net Income|Company Profit OMGA|OMIC (Singular Genomics) - Net Profit|Net Profit Regulus Therapeutics, Inc.|Net Profit SYRS|Net Financial Result Telesis Bio, Inc|Company Net Income TRACON Pharmaceuticals TCON|unitybiotechnology.com (UBX) - Company Net Income